Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a biotech company developing treatments for neurodegenerative diseases, invites shareholders and potential investors to attend its upcoming investor briefings in Sydney and Melbourne, or a webinar, to learn about the Phase 2/3 STRIKE clinical study for its drug monepantel (MPL). The sessions will be an opportunity to meet the management team and discuss the company’s strategy for MPL, which has shown promise in a Phase 1 study for ALS treatment, with a potential accelerated approval anticipated in 2026.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
